BioCentury
ARTICLE | Financial News

Aivita raises $15M series B, considers Korean clinical trial for cancer therapy

June 15, 2018 8:15 PM UTC

Cellular therapy company Aivita Biomedical Inc. (Irvine, Calif.) raised $15 million on June 11 in a series B round led by sole South Korean investor SFC Co. Ltd. (KOSDAQ:112240). The round gives it a cash runway of more than two years, according to a company spokesperson.

Aivita's lead candidate is a platform cancer immunotherapy comprising autologous dendritic cells loaded with tumor-associated antigens from autologous self-renewing tumor cells, which it calls Root of Cancer. The company said the immunotherapy could be applied to "most solid tumor types," and it is evaluating the approach in glioblastoma, melanoma and ovarian cancer. ...

BCIQ Company Profiles

AiVita Biomedical Inc.